As protein engineering and manufacturing technologies evolve, small biotech and major pharma companies alike need flexible, customized strategies that balance cost, speed and risk to accelerate drug development and approval of biotherapeutics that could address unmet medical needs.

Author: Nathalie Knabe, Senior Director Strategic Marketing, Mammalian

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center